Taipei, Taiwan — November 5, 2025 — Leads & Copy — YD Bio Limited (NasdaqGM: YDES) is supporting the global commercialization of OkaiDx™, a research‑use‑only blood test for post‑treatment breast cancer monitoring, now available through its affiliate EG Biomed US Inc.’s CLIA/CAP‑certified lab in the U.S.
YD Bio will work alongside EG BioMed to make the assay accessible to research labs, academic groups, and industry partners conducting surveillance and translational studies. OkaiDx™ utilizes cfDNA methylation profiling to generate molecular surveillance information for research settings and has been reported in journals and presented at oncology conferences.
YD Bio Founder, Chairman, and CEO Dr. Ethan Shen said the company’s involvement follows ongoing partnership activities with EG BioMed to expand U.S. lab access for molecular assays. Validation has reported performance metrics of 95.1% accuracy, 89.4% sensitivity and 96.5% specificity.
YD Bio is helping to commercialize OkaiDx™ for research applications. The test has not been cleared or approved by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. The Company expects OkaiDx™ to provide a research‑grade tool that may enable investigators to study post‑treatment monitoring approaches.
YD Bio Limited Investor Relations can be contacted by email at investor@ydesgroup.com.
Source: YD Bio Limited
